Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy
Sally A. Penfold(Albert Einstein College of Medicine), Josephine M. Forbes(Translational Research Institute), Sheila K. Patel(The University of Melbourne), Richard J. MacIsaac, Diane E. Webster(Monash University), Merlin C. Thomas(Monash University), Mark E. Cooper(Australian Regenerative Medicine Institute), Piyush Srivastava(The University of Melbourne), Louise M. Burrell(Austin Health), Karly C. Sourris(Baker Heart and Diabetes Institute), George Jerums(FibroGen (United States)), Melinda T. Coughlan(Baker Heart and Diabetes Institute), David L. Steer(Monash University)
Cited by 78
Related Papers
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Diabetic kidney disease
|Nature Reviews Disease Primers|2015|1.2k
Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes
|New England Journal of Medicine|2014|624
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
|The Lancet|2019|609
Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease
|Molecular & Cellular Proteomics|2010|537